Payment overview · 2025
General Payments
$2,697.55
104 reported records · 29 companies
Healthcare provider profile · identity verified
Tiffany Williams Rossi
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · PORT ROYAL, SC · NPI 1144991357
Verified facts
What the public records show
CMS Open Payments records show Tiffany Williams Rossi received $2,697.55 in general payments during 2025 across 104 reported records.
ABBVIE INC. accounted for 18.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nuplazid, Rexulti.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nuplazid by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Rytary by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $503.42 | 18.7% | 15 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $249.80 | 9.3% | 10 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $152.03 | 5.6% | 11 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $143.76 | 5.3% | 6 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $140.05 | 5.2% | 6 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $130.80 | 4.8% | 4 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $120.76 | 4.5% | 4 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $112.09 | 4.2% | 4 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $109.19 | 4.0% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $105.05 | 3.9% | 4 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $100.35 | 3.7% | 3 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $96.91 | 3.6% | 3 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $88.17 | 3.3% | 4 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $85.99 | 3.2% | 4 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $78.91 | 2.9% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $73.42 | 2.7% | 3 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $60.07 | 2.2% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $47.49 | 1.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $43.25 | 1.6% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $42.08 | 1.6% | 2 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.84 | 1.5% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $37.07 | 1.4% | 1 | 2025 |
| InSightec,Inc | Unresolved — no canonical attribution shown | $24.81 | 0.9% | 1 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $22.96 | 0.8% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.87 | 0.8% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.85 | 0.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.60 | 0.7% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $17.50 | 0.7% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $15.46 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,697.55 | 104 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $236.21 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $208.53 | 7 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $199.19 | 9 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $192.26 | 6 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $175.97 | 4 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $152.03 | 11 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $143.76 | 6 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $130.80 | 4 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $120.76 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $118.64 | 5 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $112.09 | 4 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $109.19 | 2 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $100.35 | 3 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $85.99 | 4 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $78.91 | 3 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $73.42 | 3 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $60.07 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $46.46 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $43.25 | 2 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $39.84 | 2 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $37.07 | 1 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $29.03 | 1 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $29.03 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $27.57 | 1 | 2025 |
Source payment records
|
|||||
| Exablate Normalized: exablate |
Device | InSightec,Inc | $24.81 | 1 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $22.96 | 1 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $20.87 | 1 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $20.02 | 1 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $19.92 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $17.85 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.60 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $17.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
55 | 12 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Donepezil Hcl | Donepezil Hcl | 352 | 93 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 328 | 69 |
| Levetiracetam | Levetiracetam | 262 | 47 |
| Memantine Hcl | Memantine Hcl | 217 | 59 |
| Escitalopram Oxalate | Escitalopram Oxalate | 173 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 121 | 27 |
| Topiramate | Topiramate | 104 | 23 |
| Gabapentin | Gabapentin | 102 | 35 |
| Fluoxetine Hcl | Fluoxetine Hcl | 95 | 18 |
| Lamotrigine | Lamotrigine | 95 | 13 |
| Clonazepam | Clonazepam | 89 | 14 |
| Lacosamide | Lacosamide | 82 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 77 | 19 |
| Pregabalin | Pregabalin | 55 | 20 |
| Rytary | Carbidopa/Levodopa | 55 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 51 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 51 | suppressed |
| Entacapone | Entacapone | 47 | 12 |
| Sertraline Hcl | Sertraline Hcl | 43 | 12 |
| Trazodone Hcl | Trazodone Hcl | 42 | suppressed |
| Primidone | Primidone | 41 | 13 |
| Rizatriptan | Rizatriptan Benzoate | 38 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 38 | 11 |
| Diazepam | Diazepam | 36 | 15 |
| Oxcarbazepine | Oxcarbazepine | 36 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 33 | suppressed |
| Zonisamide | Zonisamide | 30 | suppressed |
| Carbamazepine | Carbamazepine | 29 | suppressed |
| Olanzapine | Olanzapine | 29 | suppressed |
| Rexulti | Brexpiprazole | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 22 | suppressed |
| Nourianz | Istradefylline | 22 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Amantadine | Amantadine Hcl | 16 | suppressed |
| Butalbital-Acetaminophen | Butalbital/Acetaminophen | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 15 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Phenytoin | Phenytoin | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Gilenya | Fingolimod Hcl | 12 | suppressed |
| Levetiracetam Er | Levetiracetam | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 12 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 12 | suppressed |
| Dalfampridine Er | Dalfampridine | 11 | suppressed |
| Famotidine | Famotidine | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Rebif Rebidose | Interferon Beta-1a/Albumin | 11 | suppressed |
| Scopolamine | Scopolamine | 11 | suppressed |
| Tiagabine Hcl | Tiagabine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,697.55 · 104 records | ABBVIE INC. | AJOVY, AMYVID, AUSTEDO XR, BOTOX, BRIUMVI, CREXONT, Exablate, Gocovri, HYQVIA, INGREZZA, KISUNLA, LEQEMBI, NUPLAZID, NURTEC ODT, ONPATTRO, Ocrevus Zunovo, PURIFIED CORTROPHIN GEL, QULIPTA, QUTENZA, Qelbree, REXULTI, Rystiggo, Symbravo, TYSABRI, UBRELVY, ULTOMIRIS, VUMERITY, VYALEV, VYEPTI, VYVGART HYTRULO, WAKIX, ZEPOSIA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nuplazid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ACADIA Pharmaceuticals Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error